PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

benzonatate Side Effects

The reactions most often reported to the FDA for benzonatate (also sold as Tessalon Perles), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

15,513
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of benzonatate come from 15,513 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 15,513 reports to the FDA Adverse Event Reporting System (FAERS) for benzonatate (Tessalon Perles): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

15,513

Reports Mentioning Death

1,897

12.2% of reports — not proof the medicine caused the death

Hospitalizations

5,329

34.4% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

CHRONIC KIDNEY DISEASE
1,229
FATIGUE
1,182
COUGH
1,123
DYSPNOEA
1,096
PNEUMONIA
1,071
DIARRHOEA
1,034
NAUSEA
1,012
PAIN
890
RENAL FAILURE
871
DEATH
811
ACUTE KIDNEY INJURY
792
HEADACHE
773
DIZZINESS
605
ANXIETY
566
VOMITING
540
FALL
530
ASTHENIA
526
COVID-19
478

Who Reports Side Effects

Gender Distribution

Female 9,551 (65%)
Male 5,053 (35%)
Unknown 6

Age Distribution

0-17 205 (2%)
18-44 1,453 (15%)
45-64 3,690 (38%)
65-74 2,435 (25%)
75+ 1,896 (20%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,897 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 809
COMPLETED SUICIDE 219
RENAL FAILURE 165
CHRONIC KIDNEY DISEASE 143
CARDIAC ARREST 131
PNEUMONIA 131
TOXICITY TO VARIOUS AGENTS 130
ACUTE KIDNEY INJURY 126
DYSPNOEA 126
END STAGE RENAL DISEASE 92
FATIGUE 79
RESPIRATORY FAILURE 76
CARDIO-RESPIRATORY ARREST 67
COUGH 65
RESPIRATORY ARREST 61
NAUSEA 59
DIARRHOEA 56
ASTHENIA 55
FALL 52
NEPHROGENIC ANAEMIA 51

Reactions in Hospitalization Reports

Top reactions in 5,329 reports where hospitalization was an outcome.

Reaction Reports
PNEUMONIA 860
DYSPNOEA 626
COUGH 389
NAUSEA 386
FATIGUE 384
DIARRHOEA 365
PAIN 354
ACUTE KIDNEY INJURY 343
RENAL FAILURE 319
FALL 314
CHRONIC KIDNEY DISEASE 299
ASTHENIA 281
VOMITING 272
HEADACHE 266
DIZZINESS 243
MALAISE 220
ANXIETY 219
PYREXIA 218
HYPOTENSION 202
URINARY TRACT INFECTION 196

Compare benzonatate vs aclidinium →

What the FAERS Data Reveals About benzonatate Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 15,513 voluntary reports linked to benzonatate and its brand equivalents (Tessalon Perles), spanning 2004 through 2025. Of those, 1,897 (12.2%) listed death as an outcome and 5,329 (34.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 65% were female and 35% male; age distribution skews toward 45-64, with 3,690 reports in that bracket. The single most reported reaction is chronic kidney disease with 1,229 submissions, followed by fatigue and cough.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.